All In Biotech

Drug Trial Radar · NCT05347498

A Trial of HR091506 Tablets in Treatment of Primary Gout With Hyperuricemia in Adults

Study on Efficacy and Safety of HR091506 Tablets in Treatment of Primary Gout With Hyperuricemia in Adults

Last checked: Nov 19, 2026Latest source record: Apr 26, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

90

Planned (sponsor's estimate)

Start

Apr 30, 2022

Primary completion

Jul 31, 2022

Study completion Jul 31, 2022

Sponsor

Sponsor type
Industry
First posted
Apr 26, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is being conducted to evaluate the efficacy and safety of HR091506 tablets for treatment of primary gout with hyperuricemia in adults, and to compare the results with febuxostat tablets in the same doses.

Conditions

  • Primary Gout With Hyperuricemia in Adults

Interventions

  • HR091506 tablets + placebo of febuxostat tabletsDrug

    HR091506 tablets 40mg qd + placebo of febuxostat tablets 40mg qd in Week 1 and 2, HR091506 tablets 80mg qd + placebo of febuxostat tablets 80mg qd in Week 3 and 4

  • febuxostat tablets + placebo of HR091506 tabletsDrug

    febuxostat tablets 40mg qd + placebo of HR091506 tablets 40mg qd in Week 1 and 2, febuxostat tablets 80mg qd + placebo of HR091506 tablets 80mg qd in Week 3 and 4

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The proportion of subjects with serum uric acid level < 360μmol/L on Day 15.Time frame: on Day 15.
  2. Proportion of subjects with serum uric acid level < 360μmol/L at test of cure (TOC)Time frame: Test of cure, defined as the day after end of treatment, equivalent to Study Day 15 or 29

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.